The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 26, 2017
Filed:
Sep. 03, 2015
Janssen Pharmaceutica NV, Beerse, BE;
Francois Gaudet, Princeton, NJ (US);
Jennifer F. Nemeth, Fort Washington, PA (US);
Ricardo Attar, Lawrenceville, NJ (US);
Benjamin C. Harman, Oaklyn, NJ (US);
Yingzhe Li, Dresher, PA (US);
Jinquan Luo, Malvern, PA (US);
Ronan McDaid, Eagleville, PA (US);
Steven C. Pomerantz, Huntingdon Valley, PA (US);
Susan H. Tam, Garnet Valley, PA (US);
Alexey Teplyakov, Phoenixville, PA (US);
John Wheeler, Downingtown, PA (US);
Sheng-Jiun Wu, Broomall, PA (US);
Janssen Pharmaceutica NV, Beerse, BE;
Abstract
Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.